Author:
Kruggel Frithjof,Masaki Fumitaro,Solodkin Ana
Funder
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
National Institutes of Health
DOD ADNI
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen
Bristol-Myers Squibb Company
CereSpir, Inc.
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd
Genentech, Inc.
Fujirebio
GE Healthcare
IX-ICO Ltd.
Janssen Alzheimer Immunotherapy Research & Development, LLC.
John-son & Johnson Pharmaceutical Research & Development LLC.
Lumosity
Lundbeck
Merck & Co., Inc.
MesoScale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Piramal Imaging
Servier
Takeda Pharmaceutical Company
Transition Therapeutics
Canadian Institutes of Health Research
Northern California Institute for Research and Education
Reference85 articles.
1. ADNI General Procedure Manual. http://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf (Accessed 21 July 2016).
2. ADNI MRI Scanner Protocols. http://adni.loni.usc.edu/methods/documents/mri-protocols/ (Accessed 21 July 2016).
3. Diffusion tensor imaging of white matter degeneration in alzheimer's disease and mild cognitive impairment;Amlien;Neuroscience,2014
4. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease;Arnold;Cereb. Cortex,1991
5. Voxel-based morphometry—the methods;Ashburner;Neuroimage,2000